摘要
X-遗传的细胞凋亡抑制蛋白(XIAP)是细胞凋亡抑制蛋白(IAP)家族的一员,参与肿瘤细胞凋亡的抑制。此特性使其成为治疗癌症的靶点。本研究利用化学描述符号如指纹,主成分,对接能量参数和基于相似性的抗XIAP法,建立定量构效关系(QSAR)模型,我们已获取了相关系数(R) 值为0.803,R2值为0.645,采用SMOreg算法进行10倍交叉验证。我们已评估了这些独立的数据集中的模型,以确定其稳健性和实现相关系数(R) 值为0.793,R2值为0.628。进一步,我们用这些模型对FDA批准的药物和分子药物进行筛选,如锌数据库筛选和基于预测pIC50值对其进行优化。在对接研究中,XIAP-BIR3域的高点击率表明,碘克沙醇(DB01249)和ZINC68678304比著名的四肽抑制剂,AVPI具有更高的结合亲和力。本文综合这些模型在Web服务器中命名为“XIAPin”。望在Web服务器将有利于设计抗XIAP的好的拮抗剂。
关键词: 化学描述符,肽,定量构效关系,虚拟筛选和主成分,X染色体遗传的细胞凋亡抑制蛋白。
Current Cancer Drug Targets
Title:In Silico Designing and Screening of Antagonists against Cancer Drug Target XIAP
Volume: 15 Issue: 9
Author(s): Rahul Kumar, Jagat Singh Chauhan and Gajendra Pal Singh Raghava
Affiliation:
关键词: 化学描述符,肽,定量构效关系,虚拟筛选和主成分,X染色体遗传的细胞凋亡抑制蛋白。
摘要: X-linked inhibitor of apoptosis (XIAP) is a member of inhibitor of apoptosis (IAP) family and involved in the suppression of apoptosis in cancer cells. This property makes it a therapeutic target for the cancer therapy. In the present study, we have developed QSAR models using chemical descriptors, fingerprints, principal components, docking energy parameters and similarity-based approach against XIAP. We have achieved correlation (R) of 0.803 with R2 value of 0.645 at 10-fold cross validation using SMOreg algorithm. We have evaluated these models on independent dataset to ascertain its robustness and achieved correlation (R) of 0.793 with R2 value of 0.628. Further, we have used these models for the screening of FDA approved drugs and drug-like molecules from ZINC database and prioritized them on the basis of their predicted pIC50 values. Docking studies of top hits with XIAP-BIR3 domain shows that Iodixanol (DB01249) and ZINC68678304 have higher binding affinities than well-known tetrapeptide inhibitor, AVPI. We have integrated these models in a web server named as “XIAPin”. We hope that this web server will contribute in the designing of nifty antagonists against XIAP.
Export Options
About this article
Cite this article as:
Rahul Kumar, Jagat Singh Chauhan and Gajendra Pal Singh Raghava , In Silico Designing and Screening of Antagonists against Cancer Drug Target XIAP , Current Cancer Drug Targets 2015; 15 (9) . https://dx.doi.org/10.2174/1568009615666150706103537
DOI https://dx.doi.org/10.2174/1568009615666150706103537 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Screening for Marine Natural Products with Potential as Chemotherapeutics for Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model
Current Gene Therapy Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules
Current Drug Metabolism Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Do Quercetin and Vitamin E Properties Preclude Doxorubicin-induced Stress and Inflammation in Reproductive Tissues?
Current Cancer Therapy Reviews Exploring the Role of Phytochemicals as Potent Natural Photosensitizers in Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Tumor Markers: The Potential of “Omics” Approach
Current Molecular Medicine Formulation Development of Folic Acid Conjugated PLGA Nanoparticles for Improved Cytotoxicity of Caffeic Acid Phenethyl Ester
Pharmaceutical Nanotechnology Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Phytoestrogen Genistein and Its Pharmacological Interactions with Synthetic Endocrine-Active Compounds
Current Pharmaceutical Design Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets GCPII Imaging and Cancer
Current Medicinal Chemistry Novel Study Designs in Precision Medicine – Basket, Umbrella and Platform Trials
Current Reviews in Clinical and Experimental Pharmacology Inhibition of Alkaline Phosphatase: An Emerging New Drug Target
Mini-Reviews in Medicinal Chemistry Bioactive Compounds from Seaweed with Anti-Leukemic Activity: A Mini-Review on Carotenoids and Phlorotannins
Mini-Reviews in Medicinal Chemistry